EQL Pharma AB (FRA:7JK) Other Stockholders Equity: €24.79 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7JK EQL Pharma AB FRA:7JK
57 GF Score
Price €1.84
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB Other Stockholders Equity?

EQL Pharma AB FRA:7JK +3.25% 57 Other Stockholders Equity is €24.79 Mil as of Mar. 2026. GuruFocus rates FRA:7JK with a GF Score™ of 57/100. The stock has 4 warning signs investors should review.

EQL Pharma AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €24.79 Mil.

EQL Pharma AB's quarterly Other Stockholders Equity increased from Sep. 2025 (€23.63 Mil) to Dec. 2025 (€24.79 Mil) and increased from Dec. 2025 (€24.79 Mil) to Mar. 2026 (€24.79 Mil).

EQL Pharma AB's annual Other Stockholders Equity increased from Mar. 2024 (€0.00 Mil) to Mar. 2025 (€0.00 Mil) and increased from Mar. 2025 (€0.00 Mil) to Mar. 2026 (€24.79 Mil).

EQL Pharma AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Other Stockholders Equity Chart

EQL Pharma AB Annual Data
Trend Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 24.79

EQL Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 20.96 23.63 24.79 24.79
FRA:7JK
57GF Score
EQL Pharma AB FRA:7JK
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EQL Pharma AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €24.79 Mil mean?
EQL Pharma AB (FRA:7JK) has a Other Stockholders Equity of €24.79 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Other Stockholders Equity too high?
EQL Pharma AB's current Other Stockholders Equity is €24.79 Mil. Overall, EQL Pharma AB has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Other Stockholders Equity compare to ZTS and UTHR?
EQL Pharma AB's Other Stockholders Equity of €24.79 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Other Stockholders Equity is €24.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (FRA:7JK) has a current Other Stockholders Equity of €24.79 Mil. The current Other Stockholders Equity is €24.79 Mil. EQL Pharma AB's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For EQL Pharma AB (FRA:7JK), the current Other Stockholders Equity is €24.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges EQL:Sweden7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
57GF Score

Get the complete analysis for FRA:7JK

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price